Zinger Key Points
- The lawsuits are poised to grow due to anticipated federal regulations and increasing awareness of PFAS contamination.
- Settlements of $10.3 billion and $1.19 billion were reached between the companies and water utilities in June.
- Get two weeks of free access to pro-level trading tools, including news alerts, scanners, and real-time market insights.
In 2023, lawsuits targeting major chemical companies over PFAS contamination in U.S. drinking water resulted in settlements surpassing $11 billion.
The lawsuits, involving 3M Co MMM, The Chemours Co CC, Corteva Inc CTVA, and DuPont de Nemours Inc DD, are poised to grow due to anticipated federal regulations and increasing awareness of per- and polyfluoroalkyl substances (PFAS) contamination.
Often termed "forever chemicals," PFAS compounds resist breakdown in the environment and the human body. They're ubiquitous in numerous products like firefighting foams, non-stick pans, and cosmetics. Recognizing their threat, the U.S. Environmental Protection Agency (EPA) has tightened regulations on PFAS, emphasizing its urgency for public health and the environment.
The lawsuits, consolidated in a multidistrict litigation (MDL) in South Carolina federal court, span multiple fronts. Water utilities seek compensation for cleanup, individuals claim health issues due to PFAS exposure, and consumer class actions target PFAS-containing products, Reuters reported.
Settlements of $10.3 billion and $1.19 billion were reached between the companies and water utilities in June, highlighting the scale of the issue.
U.S. District Judge Richard Gergel warned that these lawsuits could be an existential threat to accused companies, as per the report. The potential liabilities might drive defendants to settle or seek bankruptcy protection, as seen with Kidde-Fenwal Inc.'s bankruptcy due to PFAS liabilities.
With PFAS found in the blood of 97% of Americans, the pool of potential plaintiffs is significant. According to the report, legal experts anticipate more lawsuits in 2024, targeting consumer brands and emphasizing personal injury claims.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Company
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.